NEW YORK, July 31, 2017
NEW YORK, July 31, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InVivo Therapeutics Holding Corp. ("InVivo" or the "Company") (NASDAQ: NVIV). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nviv.
The investigation concerns whether InVivo and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 31, 2017, InVivo revealed that after a third patient death, it had stopped a trial of its Neuro-Spinal Scaffold, a spinal cord injury treatment and advised investors that the it had decided to stop the trial while it discusses with the U.S. Food and Drug Administration whether to change the trial's enrollment criteria. Following this news, InVivo stock dropped as much as $0.80 per share, or 32.65%, during intraday trading on July 31, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of InVivo, you can assist this investigation by visiting the firm's site: www.bgandg.com/nviv. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-invivo-therapeutics-holding-corp-nviv-300496635.html
SOURCE Bronstein, Gewirtz & Grossman, LLC